SMS Pharma Q3FY26 Revenue Jumps 21% YoY to ₹210 Cr, PAT Up 29% to ₹23.47 Cr
SMS Pharmaceuticals reported Q3FY26 revenue of ₹210.45 crore, up 21% YoY. PAT increased by 29% to ₹23.47 crore. EBITDA grew 31% to ₹43.65 crore. The company is on track for 20% revenue growth in FY26 with 20% EBITDA margins. A ₹280 crore capex program is progressing well.
The results show solid financial performance and progress on strategic initiatives like capex, which are positive for the company's future growth prospects.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, exceeding market expectations and indicating positive business performance.
SMS Pharmaceuticals Limited has announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a significant year-on-year increase in revenue from operations, which grew by 21% to ₹210.45 crore in Q3FY26, compared to ₹173.35 crore in Q3FY25. For the nine-month period ended December 31, 2025, revenue rose by 21% to ₹648.92 crore from ₹534.55 crore in the same period last year.
EBITDA for the third quarter increased by 31% year-on-year to ₹43.65 crore, with the EBITDA margin improving to 21% from 19% in Q3FY25. The profit after tax (PAT) for Q3FY26 stood at ₹23.47 crore, marking a 29% increase from ₹18.24 crore in the previous year. The nine-month PAT also saw a substantial rise of 42% to ₹69.27 crore from ₹48.82 crore.
The company highlighted strong volume growth in key APIs and operating leverage as drivers for its performance. A ₹280 crore capex program is progressing well and is on track for completion by FY27. SMS Pharmaceuticals remains on track to deliver 20% revenue growth in FY26 with EBITDA margins of 20%. The investor presentation, accessible on the company's website, provides further details on financial performance and strategic outlook.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.